Neuromity is a biopharmaceutical company specializing in chiral switching and deuterated drugs. Led by industry veterans, Neuromity is dedicated to making better medicines for patients through their innovative process called Deuterium-Enabled Chiral Switching (DECS). By substituting a hydrogen with a deuterium at a chiral center, they effectively lock interconverting enantiomers in place, resulting in superior drugs.

This approach not only reduces development risk, shortens R&D timelines, and lowers the cost of development, but also creates new composition-of-matter patent protection. With their expertise in deuterium chemistry and chiral drug development, Neuromity is able to efficiently deliver life-improving therapies to patients who are in great need. Their ultimate goal is to optimize existing neurological drugs and provide a significant advantage for patients, leading to better medicines and happier patients